Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heartburn Clear all
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00389948
View directory record Official record
Conditions
Heartburn
Interventions
Lanzoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2007 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 3 Interventional

The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.

NCT00171457
View directory record Official record
Conditions
Heartburn, Dyspepsia
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jul 22, 2026, 4:36 AM EDT
Active, not recruiting No phase listed Observational

Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease

NCT00260572
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Questionnaires to evaluate QOL, Questionnaires to evaluate heartburn and quality of life, Questionnaire to evaluate satisfaction with treatment, Questionnaire to evaluate presence or absence of pain
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease

NCT00998244
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Overweight, Acid Reflux Disease
Interventions
Diet - very low carb or low fat
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Jul 22, 2026, 4:36 AM EDT
Not listed Not applicable Interventional

Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity

NCT01561729
View directory record Official record
Conditions
Small Bowel Obstruction, Gastrointestinal Hemorrhage
Interventions
RightSpot pH Indicator, Chest radiograph
Device · Radiation
Lead sponsor
RightBio Metrics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients

NCT04120025
View directory record Official record
Conditions
GERD
Interventions
Diaphragm Training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 22, 2026, 4:36 AM EDT
Recruiting No phase listed Observational

Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life

NCT00260559
View directory record Official record
Conditions
Esophagectomy, Esophageal Cancer
Interventions
Questionnaires
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 4:36 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of High PCO2 Solution on Esophageal Acid Sensation

NCT01128608
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
24-Hr Esohpageal pH Monitoring, PCO2 Acid Perfusion and 0.1N HCI Perfusion
Procedure
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370525
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 22, 2026, 4:36 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Demographics and Findings of Upper Endoscopy Patients

NCT00576992
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
1,177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

NCT00847210
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis

NCT00492622
View directory record Official record
Conditions
Gastroparesis, Gastroesophageal Reflux Disease
Interventions
Immediate-release omeprazole, Delayed-release omeprazole
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Jul 22, 2026, 4:36 AM EDT
Enrolling by invitation No phase listed Observational

The Johns Hopkins Heartburn Center Registry

NCT03853772
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett Esophagus, Laryngopharyngeal Reflux, Esophagitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Orange, California • Baltimore, Maryland • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms

NCT06419231
View directory record Official record
Conditions
Gut Health
Interventions
Butyrate Formulation, Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00149851
View directory record Official record
Conditions
Symptomatic Gastroespohageal Reflux Disease
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
832 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 4 Interventional Results available

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
45
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Jul 22, 2026, 4:36 AM EDT
Completed Phase 1 Interventional

Do Acid Sensing Ion Channels Contribute to Heartburn?

NCT01095133
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn
Interventions
Amiloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Jul 22, 2026, 4:36 AM EDT
Completed No phase listed Observational

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

NCT01286194
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Jul 22, 2026, 4:36 AM EDT